Abstract
The purposes of this study were to clarify the expression patterns of phosphorylated mammalian target of rapamycin (p-mTOR), mTOR, and phosphatase and tensin homolog (PTEN) in primary pancreatic neuroendocrine tumors (pNETs) and their significance in predicting clinical behaviors and postoperative outcomes. The expressions of p-mTOR, mTOR, and PTEN were assessed in 20 normal pancreatic islets and in 90 resectable pNETs using immunohistochemistry. The associations of the biomarker expressions with clinicopathologic variables and survival duration were analyzed. The percentages of G1, G2, and G3 tumors were 54.4, 43.3, and 2.2 %, respectively. A strongly positive staining was observed for both mTOR and PTEN in normal pancreatic islets, whereas negative staining was observed for p-mTOR. In primary pNETs, the mTOR and p-mTOR positive rates were 70.8 % (63/89) and 44.4 % (40/90), respectively. p-mTOR expressions strongly correlate with mTOR expressions. No significant correlation between p-mTOR and clinicopathological features was found. The high expression rate of PTEN was 56.7 % (51/90), whereas the low expression rate was 43.4 % (39/90). PTEN loss (low expression) was significantly more frequent in patients with advanced WHO grades (p = 0.004) and in patients with higher Ki-67 index (p = 0.002). In our immunohistochemical classification system, the Ki-67 index was significantly higher in the PTEN low expression/p-mTOR-positive subgroup (2.7 ± 2.5) than in the PTEN high expression/p-mTOR-negative subgroup (1.0 ± 1.7, p = 0.006). Patients in the PTEN low expression/p-mTOR-positive subgroup presented a significantly lower 5-year overall survival (OS) than those in the PTEN high expression/p-mTOR-negative subgroup (p = 0.049; 5-year OS = 79 vs. 100 %, HR = 7.0). ENETS TNM staging and major vascular invasion were independently associated factors for predicting the overall survival rate of patients (p = 0.019 and 0.011, respectively). In conclusion, positive p-mTOR expression and PTEN loss may have a synergic effect on tumorigenesis and proliferation; targeted therapy based on mTOR/PTEN signal pathway and its associated molecular mechanism may play a role in the treatment of pancreatic neuroendocrine tumors.
Similar content being viewed by others
References
Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–81.
Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394–424.
Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594–618.
Clawson GA. From devils to jobs: tracking neuroendocrine tumors. Transl Cancer Res. 2013;2:3–5.
Ito T, Tanaka M, Sasano H, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol. 2007;42:497–500.
Lo RC, Ng IO. Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res. 2011;23:245–53.
Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–92.
Yao JC, Hassan M, Han A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.
Nave BT, Ouwens M, Withers DJ, et al. Mammalian target of rapamycin is a direct target of protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344:427–31.
Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–87.
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671–88.
Peterson RT, Beal PA, Comb MJ, et al. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem. 2000;275:7416–23.
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.
Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21:163–72.
von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000;60:4573–81.
Fang Y, Vilella-Bach M, Bachmann R, et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.
Albanell J, Dalmases A, Rovira A, et al. MTOR signaling in human cancer. Clin Transl Oncol. 2007;9:484–93.
Dobashi Y, Watanabe Y, Miwa C, et al. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol. 2011;4:476–95.
Bjormnsti MA, Houghton PJ. The TOR pathway: a target for cancer chemotherapy. Nat Rev Cancer. 2004;4:335–8.
Mamane Y, Petroulakis E, LeBacquer O, et al. mTOR, translation initiation and cancer. Oncogene. 2006;25:6416–22.
Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94:195–9.
Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22:183–98.
Chung DC, Brown SB, Graeme-Cook F, et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res. 1998;58:3706–11.
Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res. 2001;61:285–92.
Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157:1097–103.
Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT–mTOR pathway. J Clin Oncol. 2010;28:245–55.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.
Crippa S, Partelli S, Boninsegna L, et al. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Ann Oncol. 2012;23:1928.
Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.
Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am. 2007;1:575–81.
Noro R, Gemma A, Miyanaga A, et al. PTEN inactivation in lung cancer and the effect of its recovery on treatment with epidermal growth factor tyrosine kinase inhibitors. Int J Oncol. 2007;31:1157–63.
Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69:3256–61.
Zhou CF, Ji J, Yuan F, et al. mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepatogastroenterology. 2011;58:2140–3.
Chen M, Van Ness M, Guo Y, et al. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2012;3:182–8.
Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med. 2013;1:6.
Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol. 2010;65:889–93.
Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–12.
Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17:1733–42.
Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321–5.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (grant ID 81071740). The authors thank the IPSEN for its editorial support.
Conflicts of interest
The authors indicated no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Han, X., Ji, Y., Zhao, J. et al. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumor Biol. 34, 2871–2879 (2013). https://doi.org/10.1007/s13277-013-0849-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-0849-1